Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 400

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.

The clinical development of MEK inhibitors

Zhao, Yujie, Adjei, Alex A.·2014·Nature Reviews Clinical Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2014.83

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 125 references

Research works printed but not linked: 11

  1. Mehra, R. et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a3007 (2012). · doi:10.1200/jco.2012.30.15_suppl.3007
  2. Harding, J. J. et al. Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets) [abstract]. J. Clin. Oncol. 31 (Suppl.), a9060 (2013). · doi:10.1200/jco.2013.31.15_suppl.9060
  3. Jain, N, C. et al. Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML) [abstract]. J. Clin. Oncol. 30 (Suppl.), a6582 (2012).
  4. Hochster, H. S. et al. The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3587 (2013). · doi:10.1200/jco.2013.31.15_suppl.3587
  5. Gupta, A. et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma [abstract]. J. Clin. Oncol. 31 (Suppl.), a9068 (2013). · doi:10.1200/jco.2013.31.15_suppl.9068
  6. Rosen, L. S. et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a14585 (2008). · doi:10.1200/jco.2008.26.15_suppl.14585
  7. Van Laethem, J. L. et al. A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): phase I dose-escalation results [abstract]. J. Clin. Oncol. 30 (Suppl.), a4050 (2012). · doi:10.1200/jco.2012.30.15_suppl.4050
  8. Infante, J. R. et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas [abstract]. J. Clin. Oncol. 30 (Suppl.), a291 (2013). · doi:10.1200/jco.2013.31.4_suppl.291
  9. Ahmed, S. R. et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), TPS3117 (2012). · doi:10.1200/jco.2012.30.15_suppl.tps3117
  10. Sosman, J. A. et al. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS145 (2011). · doi:10.1200/jco.2011.29.15_suppl.tps145
  11. Adjei, A. A. et al. Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2528 (2013). · doi:10.1200/jco.2013.31.15_suppl.2528

Cited by

See all 400

Metadata

Authors
Zhao, Y., & Adjei, A. A.
Venue
Nature Reviews Clinical Oncology
Published
2014-05-20
Volume
11
Issue
7
Pages
385-400
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W1991401350
Cited by
400
References
125
FWCI
2.85
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The clinical development of MEK inhibitors. https://app.cochat.ai/papers/10.1038/nrclinonc.2014.83
The paper
Zhao, Y., & Adjei, A. A. (2014). The clinical development of MEK inhibitors. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2014.83

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.